Dr. Peter Libby

Dr. Peter Libby is a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH) and the Mallinckrodt Professor of Medicine at Harvard Medical School (HMS).Dr. Libby received his medical degree from the University of California, San Diego School of Medicine. He completed a residency in internal medicine and a fellowship in cardiovascular disease at Peter Bent Brigham Hospital (now BWH). He also completed a research fellowship in cellular physiology at HMS. Dr. Libby is board certified in internal medicine and cardiovascular disease.The author of some 400 original peer-reviewed publications, some 450 reviews, chapters, or other publications, Dr. Libby also serves as an Editor of the leading textbook of cardiovascular medicine.  Dr. Libby's clinical and research interests include vascular biology, atherosclerosis and preventive cardiology. The research laboratory that Dr. Libby directs studies the messengers created by the body that may produce arterial plaque and blockages, as well as normal and abnormal function of smooth muscle and endothelial cells. Dr. Libby is perennially named a top cardiologist. His research has received funding from the American Heart Association and National Institutes of Health. Dr. Libby has received research recognitions on four continents including the highest research awards from the American Heart Association and American College of Cardiology, the Gold Medal of the European Society of Cardiology, the Anitschkow award from the European Atherosclerosis Society, The Ernst Jung Gold Medal for Medicine, and the Earl Benditt award for vascular biology.

Dr. Libby is rated as an Experienced provider by MediFind in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). His top areas of expertise are Atherosclerosis, Coronary Heart Disease, Abdominal Aortic Aneurysm (AAA), Percutaneous Coronary Intervention (PCI), and Heart Bypass Surgery.

His clinical research consists of co-authoring 519 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Homozygous Familial Hypercholesterolemia (HoFH).